Your browser doesn't support javascript.
loading
Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program.
Aquilante, Christina L; Trinkley, Katy E; Lee, Yee Ming; Crooks, Kristy R; Hearst, Emily C; Heckman, Simeon M; Hess, Kaitlyn W; Kudron, Elizabeth L; Martin, James L; Swartz, Carolyn T; Kao, David P.
Afiliación
  • Aquilante CL; Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Trinkley KE; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Lee YM; Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Crooks KR; Department of Family Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Hearst EC; Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Heckman SM; Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Hess KW; Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Kudron EL; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Martin JL; Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Swartz CT; UCHealth, Aurora, CO, USA.
  • Kao DP; UCHealth, Aurora, CO, USA.
Am J Health Syst Pharm ; 81(12): 555-562, 2024 Jun 11.
Article en En | MEDLINE | ID: mdl-38253063
ABSTRACT

PURPOSE:

To describe our experiences implementing and iterating CYP2C19 genotype-guided clopidogrel pharmacogenetic clinical decision support (CDS) tools over time in the setting of a large health system-wide, preemptive pharmacogenomics program.

SUMMARY:

Clopidogrel-treated patients who are genetically predicted cytochrome P450 isozyme 2C19 (CYP2C19) intermediate or poor metabolizers have an increased risk of atherothrombotic events, some of which can be life-threatening. The Clinical Pharmacogenetics Implementation Consortium provides guidance for the use of clopidogrel based on CYP2C19 genotype in patients with cardiovascular and cerebrovascular diseases. Our multidisciplinary team implemented an automated, interruptive alert that fires when clopidogrel is ordered or refilled for biobank participants with structured CYP2C19 intermediate or poor metabolizer genomic indicators in the electronic health record. The implementation began with a narrow cardiovascular indication and setting and was then scaled in 4 primary dimensions (1) clinical indication; (2) availability across health-system locations; (3) care venue (e.g., inpatient vs outpatient); and (4) provider groups (eg, cardiology and neurology). We iterated our approach over time based on evolving clinical evidence and proactive strategies to optimize CDS maintenance and sustainability. A key facilitator of expansion was socialization of the broader pharmacogenomics initiative among our academic medical center community, accompanied by clinician acceptance of pharmacogenetic alerts in practice.

CONCLUSION:

A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Farmacogenética / Inhibidores de Agregación Plaquetaria / Sistemas de Apoyo a Decisiones Clínicas / Citocromo P-450 CYP2C19 / Clopidogrel Tipo de estudio: Guideline / Prognostic_studies / Sysrev_observational_studies Límite: Humans Idioma: En Revista: Am J Health Syst Pharm Asunto de la revista: FARMACIA / HOSPITAIS Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Farmacogenética / Inhibidores de Agregación Plaquetaria / Sistemas de Apoyo a Decisiones Clínicas / Citocromo P-450 CYP2C19 / Clopidogrel Tipo de estudio: Guideline / Prognostic_studies / Sysrev_observational_studies Límite: Humans Idioma: En Revista: Am J Health Syst Pharm Asunto de la revista: FARMACIA / HOSPITAIS Año: 2024 Tipo del documento: Article